Related Experiment Video
Updated: Jun 21, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
MicroRNA-138 inhibits hypoxia-inducible factor 1α expression in breast cancer cells
Mohammad Fayyad-Kazan1, Rim ElDirani2, Michella Ghassibe-Sabbagh3
1College of Arts and Sciences, Department of Natural and Applied Sciences, The American University of Iraq-Baghdad (AUIB), Baghdad, Iraq.
Background:
Hypoxia, a critical feature during cancer development, leads to the stabilization and activation of the hypoxia-inducible factor 1-alpha (HIF-1α) to drive the expression of many target genes which in turn can promote many aspects of breast cancer biology, mainly metastasis and resistance to therapy. MicroRNAs are known to modulate the expression of many genes involved in breast cancer tumorigenesis. In this study, we examined the regulatory effect of miRNAs on HIF1α expression.
Methods:
MCF-7 and MDA-MB-231 were cultivated under normoxia or hypoxia conditions. TaqMan-Low Density Array (TLDA) was used to characterize the miRNA signatures. Wild-Type (WT) or mutated fragments of HIF-1α 3'UTR containing the miR-138 potential target site were cloned downstream of the Renilla luciferase gene in the psiCHECK-1 plasmid. Luciferase assays were then carried out. A lentiviral vector containing copGFP as a reporter gene was prepared and transduced into MCF-7 and MDA-MB-231 cells to assess the effect of identified deregulated miRNAs on HIF-1α expression.
Results:
Under hypoxic conditions, MCF-7 cells showed deregulated expression for 12 miRNAs. In the case of MDA-MB-231 cells, 16 miRNAs were deregulated in response to hypoxia. Interestingly, miR-138 that was downregulated in both MCF-7 and MDA-MB-231 cells cultivated under hypoxic conditions appeared to have a binding site in 3'UTR of HIF-1α. Moreover, our results indicated that miR-138 could down regulate HIF-1α expression, upon binding directly to its 3'UTR.
Conclusions:
Interestingly, our data highlights miR-138 as a potential therapeutic target to reduce HIF-1α expression and subsequently restrain breast cancer invasion and metastasis.
Insights
Hypoxia activates hypoxia-inducible factor 1-alpha (HIF-1α), promoting breast cancer. This study found miR-138 downregulates HIF-1α, suggesting it as a therapeutic target to inhibit cancer metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Hypoxia is a critical factor in cancer development, stabilizing hypoxia-inducible factor 1-alpha (HIF-1α).
- HIF-1α activation promotes breast cancer progression, including metastasis and therapeutic resistance.
- MicroRNAs (miRNAs) are known regulators of gene expression in cancer, including tumorigenesis.
Purpose of the Study:
- To investigate the regulatory role of miRNAs on HIF-1α expression in breast cancer cells.
- To identify specific miRNAs that are deregulated under hypoxic conditions and their effect on HIF-1α.
- To explore the potential of targeting these miRNAs for breast cancer therapy.
Main Methods:
- Culturing MCF-7 and MDA-MB-231 breast cancer cells under normoxia and hypoxia.
- Characterizing miRNA expression profiles using TaqMan-Low Density Array (TLDA).
- Validating miRNA-HIF-1α interactions using luciferase reporter assays and lentiviral transduction.
Main Results:
- Hypoxia deregulated 12 miRNAs in MCF-7 cells and 16 miRNAs in MDA-MB-231 cells.
- miR-138 was found to be downregulated in both cell lines under hypoxia.
- miR-138 directly binds to the 3'UTR of HIF-1α and downregulates its expression.
Conclusions:
- miR-138 plays a significant role in regulating HIF-1α expression under hypoxic conditions.
- Downregulation of miR-138 contributes to HIF-1α stabilization and potential breast cancer progression.
- Targeting miR-138 presents a promising therapeutic strategy to reduce HIF-1α and inhibit breast cancer invasion and metastasis.
Related Concept Videos
MicroRNAs
Regulation of Angiogenesis and Blood Supply
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Experimental RNAi

